Cabaletta Bio, Inc.
CABA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001759138
No open-market purchases or sales by Cabaletta Bio, Inc. insiders were filed in the last 90 days; 139 institutions reported holding it in 13F filings for Q2 2026, worth $490.4M in total; no superinvestor holds it.
Holders of 5% or more of CABA
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Cabaletta Bio, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Bain Capital Life Sciences Opportunities III, LP | 13G/A | 9.99%9.68M shares | – | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Adage Capital Management, L.P. | 13G/A | 9.99%9.00M shares | – | Aug 12, 20251 filing | Aug 12, 2025 | SEC |
| Alyeska Investment Group, L.P. | 13G | 9.90%8.90M shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Prudential Financial Inc | 13G/A | 7.40%10.4M shares | – | Aug 6, 20251 filing | Aug 6, 2025 | SEC |
| Jennison Associates LLC | 13G/A | 7.20%10.1M shares | – | Aug 6, 20251 filing | Aug 6, 2025 | SEC |
| Cormorant Asset Management, LP | 13G | 5.47%5.00M shares | New | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Citadel Advisors LLC | 13G | 5.20%4.82M shares | New | Jun 20, 20251 filing | Jun 20, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
11 Schedule 13D and 13G filings on Cabaletta Bio, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Aug 14, 20255:29 PM ET | Alyeska Investment Group, L.P.and 2 others | 13G | 9.90%8.90M shares | New | Jun 30, 2025 | SEC |
| Aug 14, 20254:00 PM ET | Bain Capital Life Sciences Opportunities III, LP | 13G/A | 9.99%9.68M shares | – | Jun 30, 2025 | SEC |
| Aug 14, 20253:02 PM ET | Cormorant Asset Management, LPand 1 other | 13G | 5.47%5.00M shares | New | Jun 30, 2025 | SEC |
| Aug 12, 20259:04 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 9.99%9.00M shares | – | Jun 30, 2025 | SEC |
| Aug 11, 20254:27 PM ET | Nichtberger Steven | 13G/A | 3.30%3.03M shares | –Below 5% | Jun 30, 2025 | SEC |
| Aug 6, 20254:15 PM ET | Jennison Associates LLC | 13G/A | 7.20%10.1M shares | – | Jun 30, 2025 | SEC |
| Aug 6, 20252:19 PM ET | Prudential Financial Inc | 13G/A | 7.40%10.4M shares | – | Jun 30, 2025 | SEC |
| Jul 29, 202511:23 AM ET | Vanguard Group Inc | 13G/A | 3.83%3.45M shares | –Below 5% | Jun 30, 2025 | SEC |
| Jul 16, 20257:02 PM ET | BlackRock, Inc. | 13G/A | 1.00%894.6K shares | −6.00 ppfrom 7.00%Below 5% | Jun 30, 2025 | SEC |
| Jun 20, 20255:22 PM ET | Citadel Advisors LLCand 6 others | 13G | 5.20%4.82M shares | New | Jun 12, 2025 | SEC |
| Feb 5, 20251:23 PM ET | BlackRock, Inc. | 13G/A | 7.00%3.40M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Cabaletta Bio, Inc. shares.
No Form 144 notices for Cabaletta Bio, Inc. are on file.